Venetoclax-d6

Venetoclax-d6 (ABT-199-d6) is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].

Product Specifications

Product Name Alternative

ABT-199-d6; GDC-0199-d6; RG7601-d6

UNSPSC

12352005

Target

Autophagy; Bcl-2 Family; Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(C1=CC=C(N2CCN(CC2)CC3=C(CC(C)(CC3)C)C4=CC=C(Cl)C=C4)C=C1OC5=CC6=C(NC=C6)N=C5)NS(=O)(C7=CC=C(C([N+]([O-])=O)=C7)NC([2H])([2H])C8C([2H])([2H])COCC8([2H])[2H])=O

Molecular Formula

C45H44D6ClN7O7S

Molecular Weight

874.48

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102 (4) :755-764.|[3]Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124 (25) :3738-47.|[4]Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19 (2) :202-8.